Panitumumab, sold under the brand name Vectibix, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as...
16 KB (1,421 words) - 20:12, 20 December 2023
tumors harboring a KRAS mutation (this also applied to the EGFR antibody panitumumab). This was the first genetic test to guide treatment of cancer. In July...
26 KB (2,542 words) - 19:54, 20 March 2024
nerve palsy Anti-cancer treatments such as erlotinib, cetuximab, and panitumumab, which block the function of EGFR (the epidermal growth factor receptor)...
3 KB (220 words) - 15:43, 11 May 2024
As of 2006, KRAS mutation was predictive of a very poor response to panitumumab (Vectibix) and cetuximab (Erbitux) therapy in colorectal cancer. As of...
45 KB (5,079 words) - 16:30, 16 May 2024
often[citation needed] combined with bevacizumab, aflibercept, cetuximab or panitumumab to improve efficacy and response rate. In the short term, irinotecan...
4 KB (411 words) - 21:05, 6 May 2024
mutation if it is combined with an anti-EGFR antibody such as cetuximab or panitumumab. Brigatinib is an inhibitor of ALK and mutated EGFR. ALK was first identified...
10 KB (796 words) - 23:02, 17 April 2024
conventional antibodies like trastuzumab (targeting HER2/neu), cetuximab and panitumumab (both targeting the EGF receptor), using the BiTE approach. As of 2009[update]...
9 KB (1,459 words) - 03:04, 18 May 2024
Cetuximab Dostarlimab Gemtuzumab ozogamicin Ipilimumab Nivolumab Ofatumumab Panitumumab Pembrolizumab Ranibizumab Rituximab Trastuzumab Monoclonal antibodies...
47 KB (4,798 words) - 06:45, 26 May 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab...
121 KB (13,791 words) - 00:45, 15 May 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab...
31 KB (3,413 words) - 22:16, 21 March 2024
2006: In April, Amgen acquired Abgenix, the developer of Vectibix (panitumumab), a treatment developed for certain patients with metastatic colorectal...
97 KB (7,882 words) - 18:47, 29 May 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab...
19 KB (1,444 words) - 03:34, 4 June 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab...
68 KB (5,993 words) - 03:20, 20 May 2024
colorectal cancer and squamous cell carcinoma of the head and neck. Panitumumab also targets the EGFR. It is approved for the use in the treatment of...
20 KB (2,197 words) - 05:50, 29 November 2023
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab...
12 KB (1,049 words) - 10:54, 12 January 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab...
31 KB (2,617 words) - 15:26, 6 April 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab...
92 KB (8,668 words) - 17:48, 24 May 2024
of which the three FDA approved ones are aflibercept, cetuximab and panitumumab. The primary difference in the approach to low stage rectal cancer is...
145 KB (15,735 words) - 07:05, 3 June 2024
factor (CTGF) idiopathic pulmonary fibrosis (IPF), pancreatic cancer Panitumumab Vectibix mab human epidermal growth factor receptor (EGFR) Y colorectal...
135 KB (4,013 words) - 03:57, 1 June 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab...
24 KB (2,053 words) - 21:07, 12 April 2024
AKT pathway. Panitumumab is a human mAb with high EGFR affinity that blocks ligand-binding to induce EGFR internalization. Panitumumab efficacy has been...
24 KB (2,736 words) - 00:12, 28 November 2023
pancuronium bromide (INN) Pandel Panheprin panidazole (INN) panipenem (INN) panitumumab (INN) Panixine Disperdose Panmycin panomifene (INN) Panorex Panretin...
7 KB (388 words) - 07:27, 27 December 2023
the ICG to antibodies such as daclizumab (Dac), trastuzumab (Tra), or panitumumab (Pan). ICG and laser therapy has been shown to kill human pancreatic...
26 KB (2,767 words) - 12:48, 6 May 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab...
17 KB (1,489 words) - 05:47, 7 April 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab...
22 KB (1,994 words) - 04:41, 3 January 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab...
9 KB (524 words) - 02:56, 27 April 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab...
150 KB (15,741 words) - 22:02, 27 May 2024
already been available in the market, such as cetuximab (Erbitux) and panitumumab (Vectibix), both of which are directed against HER1. However, cancer...
29 KB (3,308 words) - 18:16, 18 March 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab...
17 KB (1,735 words) - 03:22, 28 February 2024
Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab...
16 KB (1,784 words) - 04:08, 6 January 2024